Cargando…
Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein
The study aimed to investigate the antitumor efficacy of anti-LMP1 antibodies in EBV-positive nasopharyngeal and stomach cell lines and xenograft models. The study also examined the NF-κB expression and cell cycle activation of NPC-serum-exosome-associated LMP1. Anti-LMP1 antibody treatment before o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383785/ https://www.ncbi.nlm.nih.gov/pubmed/37512884 http://dx.doi.org/10.3390/microorganisms11071712 |
_version_ | 1785080996399415296 |
---|---|
author | Khenchouche, Abdelhalim Salem-Bekhit, Mounir M. Mansour, Ahd A. Alomary, Mohammad N. Wang, Xiaohui Alzahrani, Hayat Ali Hosiny, Ibrahim M. Al Taha, Ehab I. Shazly, Gamal A. Benguerba, Yacine Houali, Karim |
author_facet | Khenchouche, Abdelhalim Salem-Bekhit, Mounir M. Mansour, Ahd A. Alomary, Mohammad N. Wang, Xiaohui Alzahrani, Hayat Ali Hosiny, Ibrahim M. Al Taha, Ehab I. Shazly, Gamal A. Benguerba, Yacine Houali, Karim |
author_sort | Khenchouche, Abdelhalim |
collection | PubMed |
description | The study aimed to investigate the antitumor efficacy of anti-LMP1 antibodies in EBV-positive nasopharyngeal and stomach cell lines and xenograft models. The study also examined the NF-κB expression and cell cycle activation of NPC-serum-exosome-associated LMP1. Anti-LMP1 antibody treatment before or during cell implantation prevented tumor growth in nude mice. A small dose of antibodies resulted in complete tumor regression for at least three months after the tumors had grown in size. The consumption of antigen–antibody complexes by tumor cells limited tumor growth. In vitro experiments showed that anti-LMP1 antibodies killed EBV-positive NPC- or GC-derived epithelial cell lines and EBV-positive human B-cell lines but not EBV-negative cell lines. Treatment with anti-LMP1 reduced NF-κB expression in cells. The animal model experiments showed that anti-LMP1 inhibited and prevented NPC- or GC-derived tumor growth. The results suggest that LMP1 antibody immunotherapy could cure nasopharyngeal cancer, EBV-positive gastric carcinoma, and EBV-associated lymphomas. However, further validation of these findings is required through human clinical trials. |
format | Online Article Text |
id | pubmed-10383785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103837852023-07-30 Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein Khenchouche, Abdelhalim Salem-Bekhit, Mounir M. Mansour, Ahd A. Alomary, Mohammad N. Wang, Xiaohui Alzahrani, Hayat Ali Hosiny, Ibrahim M. Al Taha, Ehab I. Shazly, Gamal A. Benguerba, Yacine Houali, Karim Microorganisms Article The study aimed to investigate the antitumor efficacy of anti-LMP1 antibodies in EBV-positive nasopharyngeal and stomach cell lines and xenograft models. The study also examined the NF-κB expression and cell cycle activation of NPC-serum-exosome-associated LMP1. Anti-LMP1 antibody treatment before or during cell implantation prevented tumor growth in nude mice. A small dose of antibodies resulted in complete tumor regression for at least three months after the tumors had grown in size. The consumption of antigen–antibody complexes by tumor cells limited tumor growth. In vitro experiments showed that anti-LMP1 antibodies killed EBV-positive NPC- or GC-derived epithelial cell lines and EBV-positive human B-cell lines but not EBV-negative cell lines. Treatment with anti-LMP1 reduced NF-κB expression in cells. The animal model experiments showed that anti-LMP1 inhibited and prevented NPC- or GC-derived tumor growth. The results suggest that LMP1 antibody immunotherapy could cure nasopharyngeal cancer, EBV-positive gastric carcinoma, and EBV-associated lymphomas. However, further validation of these findings is required through human clinical trials. MDPI 2023-06-30 /pmc/articles/PMC10383785/ /pubmed/37512884 http://dx.doi.org/10.3390/microorganisms11071712 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khenchouche, Abdelhalim Salem-Bekhit, Mounir M. Mansour, Ahd A. Alomary, Mohammad N. Wang, Xiaohui Alzahrani, Hayat Ali Hosiny, Ibrahim M. Al Taha, Ehab I. Shazly, Gamal A. Benguerba, Yacine Houali, Karim Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein |
title | Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein |
title_full | Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein |
title_fullStr | Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein |
title_full_unstemmed | Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein |
title_short | Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein |
title_sort | suppression of nasopharyngeal and gastric tumor growth in a mouse model by antibodies to epstein–barr virus lmp1 protein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383785/ https://www.ncbi.nlm.nih.gov/pubmed/37512884 http://dx.doi.org/10.3390/microorganisms11071712 |
work_keys_str_mv | AT khenchoucheabdelhalim suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT salembekhitmounirm suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT mansourahda suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT alomarymohammadn suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT wangxiaohui suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT alzahranihayatali suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT hosinyibrahimmal suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT tahaehabi suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT shazlygamala suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT benguerbayacine suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein AT houalikarim suppressionofnasopharyngealandgastrictumorgrowthinamousemodelbyantibodiestoepsteinbarrviruslmp1protein |